
Pierre E. Etienne MD, FRCPC

6875 Lasalle Boulevard,
Verdun, Qc, H4H 1R3
E.2213.2

Email: pierre.etienne@douglas.mcgill.ca

PROFESSIONAL PROFILE

Psychiatrist with extensive management experience in large and small pharma.
Proven track record of successes in early clinical research, clinical operations, including the execution of large clinical programs, regulatory submissions and licensing.
Co-Director of the Stop-AD program and Director of the Clinical Research Division at the Douglas Mental Health University Institute

PROFESSIONAL EXPERIENCE

Targanta Therapeutics, Inc. September 2006 – December 2008

Chief Development Officer

Orchestrated the assembly of the NDA for oritavancin, submitted in February 2008 and the EMEA application submitted in April of the same year.

Completed a 300 patients Phase 2 program to evaluate more convenient oritavancin dosage regimens (SIMPLIFI) in complicated skin and skin structure infections (cSSSI).

PhageTech Inc. (now Targanta Therapeutics, Inc. June 2003 – September 2006)

President and Chief Executive Officer

Transformed a Montreal-based small biotech at the screening stage into a small pharmaceutical company (80 employees) focused on hospital products for serious infections.

- Led the company through 2 rounds of financing that made possible the acquisition of oritavancin (an i.v. glycopeptide for Gram + infections) and the migration of the company from Canada to the USA.
- Together with Chairman of the Board (Alex Moot, Seaflower Ventures), orchestrated the acquisition of oritavancin from InterMune (ITMN) and Lilly (LLY).

- Together with Tom Parr (CSO) re-negotiated better licensing terms with Eli Lilly, moved the company from Canada to the US and established clinical, regulatory and manufacturing functions in Indianapolis.
- Resolved technical risks that had prevented InterMune from out-licensing oritavancin.
- In anticipation of the need to take the company public before assembling a commercial and marketing organization to launch oritavancin, stepped down to facilitate the CEO succession plan and focus on the oritavancin NDA submission and EMEA application as Chief Development Officer. The company went public (NASDAQ:TARG) in October 2006. (Targanta was purchased by The Medicine Company (MEDCO) in January 2009).

Pfizer, Inc. Vice President, World Wide Study Management . Sept 2001– June 2003

Implemented all full development programs (phase 2b and 3) world wide (4 R&D sites: Groton/New London, Ann Arbor, Sandwich, LaJolla)

- 20,000 new pts/yr
- 1100 employees including contractors.

Pfizer, Inc. Executive Director, US Clinical and Business Operations. March 2000 – Sept 2001

Led clinical operations (study management and monitoring), data management, biometrics and IT services for USA, Canada, Latin America, India and China.

- Managed a budget of \$110 M /yr
- 550 employees including contractors.

Pfizer, Inc. Executive Director, International Clinical Research Group and Executive Director, Naturaceuticals Group. Oct 1997 – March 2000

Led clinical operations (study management and monitoring) for Canada, Latin America, India and China

Established the first clinical operations group in India that allowed inclusion of clinical results from India in registration studies for FDA and EMEA applications.

Built a virtual intra-company (6 employees) focused on the licensing, clinical development and registration of naturaceutical products

Pfizer, Inc. Group Director, International Clinical Research Group. Aug 1996 – Oct 1997

Established the data management and biostatistics group in India for Pfizer Central Research.

Pfizer, Inc. Group Director, Early Clinical Research Group. Oct 1992 – June 1996

Responsible for all Phase 1 and Phase 2A programs for Japan and USA discovered compounds.

- Approximately 40 different INDs over that period of time including ziprasidone (Zeldox, Geodon) and CP-118-951, Aricept backup.
- Managed a budget of \$12 M US /yr
- 43 employees.

Pfizer, Inc. Director, Experimental Medicine. Dec 1989 – Oct 1992

Managed all Phase 2A programs for Japan and US discovered compounds.

- Managed a budget of \$4M US/yr
- 15 employees.

CIBA-Geigy, Ltd. Associate Director, Clinical Biology Group. April 1985 – March 1988

Designed and executed proof of concept studies in the early development of CNS drugs. Under Frank Douglas' leadership, contributed to the creation of the first translational medicine program (from laboratory to bedside) in the pharmaceutical industry. The program was disbanded after the repatriation of preclinical CNS research program to Basel.

Academic Experience

July 2012 – present	Associate Professor (Psychiatry), McGill University
March 1988 – Dec 1989	Associate Professor (Psychiatry), tenured, McGill University
June 1982 – April 1985	Assistant Professor (Psychiatry), McGill University
July 1978 – June 1982	Lecturer (Psychiatry), McGill University

Principal investigator on the first Medical Research Council of Canada (MRC) program research grant ever attributed to the Department of Psychiatry at McGill University (1986-1989). This program grant had three components: clinical research, neurochemistry and (quantitative) neuropathology and was focused on the cholinergic hypothesis of Alzheimer's disease. The previous grant (single investigator grant) had been a clinical research grant to evaluate the safety and efficacy of lecithin in the symptomatic treatment of Alzheimer's disease patients. This grant followed the publication of the first North American study of an attempt at treating Alzheimer's disease patients with a cholinergic agent.

EDUCATION

Université de Liège, Belgium	MD	1972
McGill University, Montreal	Psychiatry	1978

ASSOCIATIONS, VOLUNTEER WORK AND ACTIVITIES

- With Dr. Robert Rubin M.D and Dr. Alan Moses, M.D. founded the Harvard-MIT Clinical Investigator Training Program. This program (supported by Pfizer) is aimed at improving the formation of future clinical research investigators and focused on the translation of research results from the laboratory to the bedside, 1994-now.
-

ACADEMIC PUBLICATIONS – (excluding abstracts and presentations at meetings):

Note: Publications generated by members of the groups I led in early clinical research from 1989 to 1996 are not included.

Key publications are boldfaced.

1. Lal, S., Allen, J., Etienne, P., Sourkes, T.L. and Humphreys, P. (1976). Dopaminergic function in Gilles de la Tourette's syndrome, Sydenham's chorea and torsion dystonia. Clin. Neurol. Neurosurg. 79:66-69.
 2. Young, S.N., Etienne, P. and Sourkes, T.L. (1976). Relationship between rat brain and cisternal CSF tryptophan concentrations. J. Neurol. Neurosurg. Psychiat. 39:239-243.
 3. **Etienne, P., Young, S.N. and Sourkes, T.L. (1976). Inhibition by albumin of tryptophan uptake by rat brain. Nature 262:144-145.**
 4. **Etienne, P., Gauthier, S., Johnson, G., Collier, B., Mendis, T., Dastoor, D., Cole, M. and Muller, H.F. (1977). Clinical effects of Choline in Alzheimer's disease. Lancet 1:508-509.**
 5. **Etienne, P., Gauthier, S., Dastoor, D., Collier, B. and Ratner, J. (1978). Clinical effects of lecithin in Alzheimer's disease. Lancet 2:1206.**
 6. Etienne, P., Gauthier, S., Dastoor, D., Collier, B. and Ratner, J.: Alzheimer's disease: Clinical effect of lecithin treatment. In: Nutrition and the Brain. Vol. 5: Choline and Lecithin in Brain Disorders. Eds: Barbeau, A., Growdon, J.H. and Wurtman, R.J. Raven press, 1979. pp. 389-395.
 7. Etienne, P., Gauthier, S., Dastoor, D., Collier, B. and Ratner, J.: Alzheimer's disease: Clinical effect of lecithin treatment. In: Alzheimer's disease, early recognition of potentially reversible deficits. Eds: Glen, A.I.M. and WEhalley, L, J. Churchill Livingstone, 1980.
 8. Lal, S., Etienne, P., Collier, B., Nair, N.P.V., Thavundayil, J., Rastogi, R., Schwartz, G., Pullman, J. and Guyda, H. (1981). Effect of sleep deprivation on dopamine receptor function in normal subjects. J. Neural Transmission 50:38-45.
-

9. Lal, S., Etienne, P., Thavundayil, J., Nair, N.P.V., Collier, B., Rastogi, R. Guyda, H. and Schwartz, G. (1981). Effect of Choline on central dopaminergic function in normal subjects. *J. Neur. Trans.* 50:29-37.
 10. Etienne, P., Dastoor, D., Goldapple, E., Johnson, S., Rochefort, E. and Ratner, J. (1981). Adverse effects of medical and psychiatric work-up in demented geriatric patients. *Amer. J. Psychiatry* 138:4.
 11. **Etienne, P., Dastoor, D., Gauthier, S., Ludwick, R. and Collier, b. (1981). Alzheimer disease: Lack of effect of lecithin treatment for 3 months. *Neurology* 31:1552-1554.**
 12. McCoy, S.N. Thavundayil, J.X., Schwartz, G. and Etienne, P., (1982). Lithium ratio and hypertension in manic depressive patients. *Am. J. Psychiatry* 139:247-248.
 13. Lal, S., Nair, N.P.V., Iskandar, H.L., Etienne, P., Wood, P.L., Schwartz, G. and Guyda, H. (1982). Effect of domperidone on apomorphine-induced growth hormone secretion in normal men. *J. Neur. Trans.* 54:75-84.
 14. Wood, P.L., Etienne, P., Lal, S., Gauthier, S., Cajal, S. and Nair, N.P.V. (1982). Reduced lumbar CSF somatostatin levels in Alzheimer's disease. *Life Sci.* 29:2593-2598.
 15. Wood, P.L., Etienne, P., Lal, S. and Nair, N.P.V. (1982). Gabaergic regulation of nigrostriatal neurons: Coupling of benzodiazepine and GABA receptors. *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.* 6:471-474.
 16. Lal, S. Nair, N.P.V., Iskandar, H., Thavundayil, J., Etienne, P., Wood, P.L. and Guyda, H. (1982). Drug induced growth hormone and prolactin responses in schizophrenia research. *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.* 6:631-637.
 17. Robitaille, Y, Wood, P.L., Etienne, P. Lal, S., Finlayson, M.H., Gauthier, S. and Nair, N.P.V. (1982). Reduced cortical choline acetyl-transferase activity in Gerstmann-Stroussler syndrome. *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.* 6:529-531.
 18. Nair, N.P.V., Lal, S. Iskandar, h.I., Etienne, P., Wood, P.L. and Guyda, H. (1982). Effect of sulpiride an atypical neuroleptic on apomorphine-induced growth hormone secretion. *Brain Res. Bull.* 8:587-591.
 19. Wood, P.L., Nair, N.P.V., Lal, S. and Etienne, P. (1983). Buspirone: A potential atypical neuroleptic. *Life Sci.* 33:269-273.
-

20. Lal, S., Nair, N.P.V., Iskandar, H.I., Wood, P.L., Etienne, P. and Guyda, H. (1983). Clinical studies on the dopamine receptor mediating apomorphine-induced growth hormone secretion. Pp. 431-442. Publishing House of the Hungarian Academy of Sciences. Eds: Endroczi et al.
 21. Etienne, P. (1983). Treatment of Alzheimer's disease with lecithin. In: Alzheimer's disease. Edited by B. Reisberg. The Free Press and Collier, Macmillan, Inc.
 22. Nair, N.p.V., Lal, S., Wood, P.L., Eugenio, E., Thavundayil, J., Lizondo, E. Etienne, P. and Guyda, H. (1983). Effect of cholecystokinin peptides on dopaminergic function in man. *Neuroendoc. Letters* 5:181.
 23. Wood, P.L., McQuade, P.S., Etienne, P., Lal, S. and Nair, N.P.V. (1983). Differential action of classical and atypical neuroleptics on mouse nigrostriatal neurons. *Prog. Neuro-Psychopharmacol. & Biol. Psych.* 7:765-768.
 24. Wood, P.L., Nair, N.P.V., Etienne, P., Lal, S., Gauthier, S., Robitaille, Y. Bird, E.D., Palo, J., Haltia, N. and Poetau, A. (1983). Lack of cholinergic deficit in the neocortex in Pick's disease. *Prog. Neuro-Psychopharmacol. & Biol. Psych.* 7:725-727.
 25. Lal, S. Nair, N.P.V., Eugenio, H. Thavundayil, J., Lizondo, E., Wood, P.L., Etienne, P. and Guyda, H. (1983). Neuroendocrine evaluation of CCK peptides on dopaminergic functions in man. *Prog. Neuro-Psychopharmacol. & Biol. Psych.* 7:537-544.
 26. Wood, P.L., Etienne, P., Lal, S., Nair, N.P.V., Finlayson, N.H., Gauthier, S., Palo, J., Haltia, M. Paeteau, A. and Bird, E.D. (1983). A post-mortem comparison of the cortical cholinergic system in Alzheimer's disease and Pick's disease. *J. Neurol. Sci.* 62:211-217.
 27. Parent, A., Csonka, C. and Etienne, P. (1984). The occurrence of large acetylcholinesterase-containing neurons in human neostriatum as disclosed in normal and Alzheimer-diseased brains. *Brain Res.* 291:154-158.
 28. Nair, N.P.V., Lal, S., Thavundayil, J.X., Wood, P.L., Etienne, P. and Guyda, H. (1984). CCK-33 antagonizes apomorphine-induced growth hormone secretion and increases basal prolactin levels in man. *Neuropeptides* 4:281-291.
 29. Lal, S., Ackman, D., Thavundayil, J.X., Kiely, M.E. and Etienne, P. (1984). Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. *Prog. Neuro-Psychopharmacol. & Biol. Psych.* 8:695-699.
-

-
30. Wood, P.L., Etienne, P., Lal, S. and Nair, V. (1984). Benzodiazepines and gabaergic regulation of nigrostriatal neurons: Lack of tolerance. *Prog. Neuro-Psychopharmacol. & Biol. Psych* 8:779-783.
 31. Lal, S., Wood, P.L., Kiely, M.E., Etienne, P., Gauthier, S., Stratford, J., Ford, R.M., Dastoor, D. and Nair, N.P.V. (1984). CSF acetylcholinesterase in dementia and in sequential samples of lumbar CSF. *Neurobiol. Aging* 5:269-274.
 32. McQuade, P.S., Etienne, P., Robitaille, Y., Wood, P.L. and Nair, N.P.V. (1985). Choline acetyltransferase activities and amino acid concentrations in the temporal cortex, caudate nucleus basalis of Meynert in Alzheimer's disease and controls. In: *Clinical and Pharmacological Studies in Psychiatric Disorders*. G.D. Burrows, T.R. Norman, L. Dennerstein (Eds.), *Biological Psychiatry – New Prospects: 5*. John Libbey, London-Paris, 1985. pp. 306-315.
 33. Quirion, R., Csonka, C. Etienne, P., Nair, N.P.V., Robitaille, Y. and Gaudreau, P. (1985). Autoradiographic localization of cholecystokinin (CCK) Receptors in human brain. *Ann. N.Y. Acad. Sci.* 448:624-626.
 34. Nair, N.P.V., Lal, S., Eugenio, H., Lizondo, E., Thavundayil, J.X., Wood, P.L., Etienne, P. and Guyda, H. (1986). CCK-8 antagonizes apomorphine-induced growth hormones secretion in normal subjects. *Horm. Metab. Res.* 18:53-55.
 35. Etienne, P., Robitaille, Y., Gauthier, S. and Nair, N.P.V. (1986). Nucleus basalis neuronal loss of neuritic plaques in advanced Alzheimer's disease. *Can. J. Physiol. Pharmacol.*, 64:318-324.
 36. Quirion, R., Etienne, P., Nair, N.P.V., Pelletier, G. and Gaudreau, P. (1986). Neuropeptide receptors in human forebrain: an autoradiographic study. *Ann. N.Y. Acad. Sci.* 463:128-130.
 37. Etienne, P., Robitaille, Y. and Parent, A. Cell counts in the nucleus basalis of Meynert and the supraoptic nucleus in Alzheimer-diseased brains. In: *Dynamics of cholinergic function*. Edited by I. Hanin. Plenum Press, New York, 1986. pp. 243-250.
 38. Quirion, R., Martel, J.C. Robitaille, Y., Etienne, P., Wood, P., Nair, N.P.V. and Gauthier, S. (1986). Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. *Can. J. Neurol. Sci.* 13:503-510.
-

39. Moroni, F., Lombardi, G., Robitaille, Y. and Etienne, P. (1986). Senile dementia and Alzheimer's disease. Lack of changes of the cortical content of quinolinic acid. *Neurobiol. Aging*. 7:249-253.
 40. Moroni, F., Lombardi, G., Carla, V., Lal, S., Etienne, P. and Nair, N.P.V. (1986). Increase in the content of quinolinic acid in cerebro-spinal fluid and frontal cortex of patients affected by hepatic failure. *J. Neurochem*. 47:1667-1671.
 41. Etienne, P., Robitaille, Y., Wood, P., Gauthier, S., Nair, V. and Quirion, R. (1986). Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. *Neurosci*. 19:1279-1291.
 42. Sinton, C. McCullough, J.R., Ilmoniemi, R.J. and Etienne, P., (1986). Modulation of auditory evoked magnetic fields by benzodiazepines. *Neuropsychobiology*. 16:215-218.
 43. Etienne, P. and Beaudry, M. (1987). Calcium dependent aspects of synaptic plasticity, excitatory amino acid neurotransmission, brain aging and schizophrenia: a unifying hypothesis. *Neurobiol. Aging*. 8:362-366. (Commentary).
 44. Etienne, P., and Zubenko, G. Does Captopril elevate Mood? (1987) *TIPS*. 8:329-330. (Commentary).
 45. Boast, C. Gerhardt, S., Pastor, G. Lehmann, J., Etienne, P. and Liebman, J. The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils. (1988) *Brain Research*. 42:345-348.
 46. Smeesters, C. Chaland, P., Giroux, L., Moutquin, J.M., Etienne, P., Douglas F., Carman, J., St-Louis, G., Daloz, P. (1988). Prevention of acute cyclosporine nephrotoxicity by a thromboxane synthetase inhibitor. *Transplantation Proceedings* 20:663-669.
 47. Etienne, P. and Baudry, M. (1990). Excitatory amino acids, brain aging and schizophrenia. *J. Neural Transmission, Suppl.* 29:39-47.
 48. Landfield, P., Cadwallader, L. Vinsant, S. Fleenor, D., Kerr, S., Campbell, L., Etienne, P. (1989). Effects of long term alterations of dietary calcium and magnesium on indices of rat brain aging and bone structure. In: *The Potential of Nutritional Modulation of Aging Processes*. Edited by D. Ingram and G. Livingston. Food and Nutrition Press, Inc. Westport. Conn.
-

49. Etienne, P. and Hakim, A. (1989). Clinical evaluation of compounds modifying acute and chronic neurodegeneration in the CNS. In: Current and future trends in anticonvulsant, stroke and anxiety therapy. Edited by M. Williams and J. Emmett. Alan R. Liss, Inc., New York.
 50. Lehmann, P., Etienne, P., Cheney, D. and Wood, P. (1990). NMDA receptors and their ion channels. In: Neurotransmitters and Epilepsy. Edited by R. Fisher and J. Coyle. Alan R. Liss, Inc. New York.
 51. Etienne, P. and Hakim, A. Clinical testing of compounds and modifying acute and chronic neurodegeneration in the CNS. *Prog. Clin. Biol. Res.* 1990 361:387-407.
 52. Chouinard, G. Beauclair, I., Geiser, R. and Etienne, P. A pilot study of magnesium aspartated hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. *Prog. Neuro-Psychopharmacol. & Biol. Psych.* 1990 14 (2): 121-180.
-